RTN4 and multiple sclerosis: Nogo-A and NgR1 signaling is also a potentially important plasticity-limiting mechanism, and early work has demonstrated that anti-Nogo antibody/NgR1 receptor antagonists may be helpful to induce new periods of experience-dependent plasticity, for diseases ranging from spinal cord injury, to stroke and multiple sclerosis (Schwab and Strittmatter, 2014).